SKYE NASDAQ
Skye Bioscience, Inc.
1W: -10.8%
1M: -7.4%
3M: -7.3%
YTD: -17.4%
1Y: -61.2%
3Y: -80.7%
5Y: -96.8%
$0.75
+0.02 (+2.87%)
Weekly Expected Move ±13.4%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$25.5M
52W Range0.566-5.75
Volume128,618
Avg Volume514,531
Beta3.02
Dividend—
Analyst Ratings
Company Info
CEOPunit S. Dhillon
Employees16
SectorHealthcare
IndustryBiotechnology
IPO Date2014-11-26
Websiteskyebioscience.com
11250 El Camino Real
San Diego, CA 92130
US
San Diego, CA 92130
US
858 410 0266
About Skye Bioscience, Inc.
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.
Latest News
Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1
UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
Skye Bioscience GAAP EPS of -$0.32
Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Sharp John P | 0 | — | 2026-03-31 | |
| Smith Karen L. | A-Award | 75,000 | $0.61 | 2026-03-31 |
| Twitty Christopher | A-Award | 200,000 | $0.61 | 2026-03-31 |
| Twitty Christopher | A-Award | 150,000 | $0.61 | 2026-03-31 |
| Twitty Christopher | A-Award | 75,000 | $0.61 | 2026-03-31 |